English: Description of Goods 3,20-dione; adenosine; alpha,4-dibromo-2-fluorotoluene; alpha-acetyl-gamma-butyrolactone; ammonium (Z)-2-methoxyimino-2-(2-furyl)acetate; benzhydryl 3-hydroxy-7-(phenylacetamido)cepham-4-carboxylate; benzyl (1R,2S)-3-chloro-2-hydroxy-1-(phenylthiomethyl)propylcarbamate; benzyl (1S,2S)-3-[(3S,4aS,8aS)-3-tert-butylcarbamoylperhydro-2isoquinolyl]-2-hydroxy-1-(phenylthiomethyl)propylcarbamate; benzyl L-alaninate--p-toluenesulfonic acid (1:1); benzyl(2-pyridyl)amine; cytosine; danaparoid sodium; dibenzoyl-L-tartaric acid; dimethyl{2-[5-(1H-1,2,4-triazol-1-ylmethyl)indol-3-yl]ethyl}amine; ethyl (1-cyanocyclohexyl)acetate; ethyl (7-chloro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-1-yl)acetate; ethyl (S)-3-(4-aminophenyl)-2-phthalimidopropionate hydrochloride; ethyl (S)-3-{4-[bis(2-chloroethyl)amino]phenyl}-2-phthalimidopropionate hydrochloride; ethyl (Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetate; ethyl [3-(cyanomethyl)-4-oxo-3,4-dihydrophthalazin-1-yl]acetate; ethyl 1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3carboxylate; ethyl 1H-tetrazole-5-carboxylate, sodium salt; ethyl 2-(hydroxyimino)-2-[2-(tritylamino)thiazol-4-yl]acetate hydrochloride; ethyl 7-chloro-2-oxoheptanoate, in the form of a solution in toluene; ethyl 7-chloro-2-oxoheptanoate; ethyl DL-mandelate; ethyl N-{2-[(acetylthio)methyl]-3-(o-tolyl)-1-oxopropyl}-L-methionate; indan-5-yl hydrogen phenylmalonate; Intermediate concentrate obtained from a genetically-modified Escherichia coli fermentation medium, containing human granulocytemacrophage colony-stimulating factor, used for the manufacture of medicaments of heading No. 30.02; Intermediate concentrate obtained from a genetically-modified Escherichia coli fermentation medium, containing human interferon alpha-2b, used for the manufacture of medicaments of heading No. 30.02; Intermediate concentrates obtained from a Micromonospora inyoensis fermentation medium used for the manufacture of the antibiotics sisomicin (INN) and netilmicin (INN); Intermediate concentrates obtained from a Micromonospora purpurea fermentation medium used for the manufacture of the antibiotics gentamicin sulfate (INNM) and isepamicin (INN); isopropyl 2,3-dihydro-1H-pyrrolizine-1-carboxylate; isopropyl[2-(piperazin-1-yl)-3-pyridyl]amine; L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-Lleucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-Lleucyl-L-leucyl-L-leucyl-L-leucyl-L-lysine; magnesium bis[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4yl)methylamino]methanesulfonate; meso-N-benzyl-3-nitrocyclopropane-1,2-dicarboximide; methyl (2R,3S)-2,3-epoxy-3-(4-methoxyphenyl)propionate;
French: Dénomination des marchandises 7-chloro-2-oxoheptanoate d'éthyle, sous la forme d'une solution dans le toluène; 7-chloro-2-oxoheptanoate d'éthyle; DL-mandélate d'éthyle; N-{2-[(acétylthio)méthyl]-3-(o-tolyl)-1-oxopropyl}-L-méthionate d'éthyle; hydrogénophénylmalonate d'indane-5-yle; Concentré intermédiaire issu d'un milieu de fermentation d'Escherichia coli génétiquement modifié, contenant un facteur de stimulation de colonies granulocytes macrophages, destiné à la fabrication de médicaments de la position no 30.02; Concentré intermédiaire issu d'un milieu de fermentation d'Escherichia coli génétiquement modifié, contenant de l'interféron humain alpha-2b, destiné à la fabrication de médicaments de la position no 30.02; Concentrés intermédiaires issus d'un milieu de fermentation de Micromonospora inyoensis, destinés à la fabrication des antibiotiques sisomicine (DCI) et nétilmicine (DCI); Concentrés intermédiaires issus d'un milieu de fermentation de Micromonospora purpurea, destinés à la fabrication des antibiotiques sulfate de gentamicine (DCIM) et isépamicine (DCI); 2,3-dihydro-1H-pyrrolizine-1-carboxylate d'isopropyle; isopropyl[2-(pipérazine-1-yl)-3-pyridyl]amine; L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-Lleucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-Lleucyl-L-leucyl-L-leucyl-L-leucyl-L-lysine; bis[(2,3-dihydro-1,5-diméthyl-3-oxo-2-phényl-1H-pyrazole-4-yl) méthylamino]méthanesulfonate de magnésium; méso-N-benzyl-3-nitrocyclopropane-1,2-dicarboximide; (2R,3S)-2,3-époxy-3-(4-méthoxyphényl)propionate de méthyle; (2R,3S)-3-benzamido-2-hydroxy-3-phénylpropionate de méthyle; (4-nitrophényl)-L-alaninate de méthyle; 1H-1,2,4-triazole-3-carboxylate de méthyle; 2-(3-nitrobenzylidène)-3-oxobutyrate de méthyle; 7-[(3RS)-3-hydroxy-5-oxocyclopent-1-ényl]heptanoate de méthyle; di(acétate) de N,N'-dibenzyléthylènediammonium; 7,7-dioxyde de N-(5,6-dihydro-6-méthyl-2-sulfamoyl-4H-thiéno[2,3b]thiopyranne-4-yl)acétamide; N-(9-acétyl-6-oxo-6,9-dihydro-1H-purine-2-yl)acétamide; N-(benzyloxycarbonyl)-L-valine; N-(benzyloxycarbonyl)-S-phényl-L-cystéine; N-(tert-butyl)-3-méthylpyridine-2-carboxamide; acide N-[(R)-2-({(R)-2-[(2-adamantyloxycarbonyl)amino]-3-(1H-indole-3yl)-2-méthyl-1-oxopropyl}amino)-1-phényléthyl]succinamique--1désoxy-1-méthylamino-D-glucitol (1:1); N-[2-isopropylthiazole-4-ylméthyl(méthyl)carbamoyl]-L-valine; acide N-{5-[(1,4-dihydro-2-méthyl-4-oxoquinazoline-6-ylméthyl) méthylamino]-2-thénoyl}-L-glutamique; omega-conotoxine M VIIA; (2R,5R,6S)-6-[(R)-1-hydroxyéthyl]-3,7-dioxo-1-azabicyclo[3.2.0]heptane2-carboxylate de p-nitrobenzyle; bis{3-[1-(3,4-diméthoxybenzyl)-6,7-diméthoxy-1,2,3,4-tétrahydro-2isoquinolyl]propionate} de pentaméthylène--acide oxalique (1:2); chloroformiate de pentyle; 1-(1-hydroxyéthyl)-5-méthoxy-2-oxo-1,2,5,6,7,8,8a,8b-octahydroazéto[2,1-a]isoindole-4-carboxylate de potassium; purine-6(1H)-one; quinuclidine-3-ol;